Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) and Omega Laboratories, ...

Omega Laboratories, Inc. ("Omega"), and Cannabix Technologies Inc. ("Cannabix") (CSE: BLO) (OTCID: BLOZF) announce the development and validation of a DOT-like drug-test panel for breath testing. The ...

Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the "Company" or "Cannabix") and Omega Laboratories, ...

Automated quality control using rapid PCR assays is replacing 28-day culture tests, cutting biopharmaceutical lot release ...

As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How is the field adapting to meet these new demands?

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...

This article explores how new technologies in plasma proteomics enable the simultaneous analysis of thousands of proteins, ...

A novel portable device detects abnormalities in eye movements to determine the probability of a concussion, along with ...

Cannabix Technologies (CSE:BLO)(USOTC:BLOZF)(Frankfurt: 8CT)has announced a potentially transformative advancement in the ...

Researchers at Washington University School of Medicine have developed a method to predict when a person will develop ...

From early research to quality control, maintaining analytical continuity is no easy task. Could a single sequencing workflow help simplify analytical assessment?